RT Journal Article
SR Electronic
T1 Some Clinical and Immunological Features of Imported COVID-19 Cases in Mongolia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253849
DO 10.1101/2021.03.17.21253849
A1 Batmunkh, Munkh-Undrakh
A1 Lkhagvasuren, Enkhsaikhan
A1 Ravjir, Oyungerel
A1 Sandag, Tsogtsaikhan
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253849.abstract
AB SARS-CoV-2 disturbs the normal immune responses causing an uncontrolled inflammatory response in patients with severe COVID-19. The pattern of the immune response to the SARS-CoV-2 in individuals may fluctuate. Some have a virus-dependent protective immune response resulting in asymptomatic or mild disease with elimination of the virus within 7-10 days after onset of infection. Others develop virus non-dependent uncontrolled hyper-inflammation in the later period, leading to severe disease with cytokine storm, acute respiratory distress syndrome, disseminated intravascular coagulation and multi-organ failure.Methods The serum of 72 patients was investigated for titers of 15 cytokines and chemokines using Enzyme-linked immunosorbent assay (ELISA) kits in the serum of peripheral blood samples. The means of groups were compared using ANOVA followed by Tukey multiple post hoc comparisons if the ANOVA p-value was <0.05.Results Patients with pulmonary infiltrates on CT demonstrated a lower percentage of eosinophils (1.38±1.46%) and elevated level of serum CRP (8.57±19.10 mg/dL) compared to patients without pulmonary infiltrates (2.52±1.47% and 1.96±3.02 mg/dL respectively; p<0.05). ROC analysis for patients aged ≥35 years showed patients with mild disease (n=3) had a significantly higher titer of IL-1β and MCP-1 (AUC, 0.958 and 0.917 respectively, p<0.05) compared to patients with moderate disease (n=7).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study was requested by the Ministry of Health of Mongolia on an emergency basis and was carried out with the financial support of the Science and Technology Foundation, an agency of the Government of MongoliaFunding StatementStudy was conducted with the financial support of the Foundation for Science and Technology under the Government of Mongolia. Technical assistance was provided by the Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia and National Center for Communicable Diseases, MoH, Ulaanbaatar, Mongolia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study design and methodology discussed and approved at the meeting of the Committee on Medical Ethics under the Ministry of Health of Mongolia (date July 8, 2020), and permission to conduct an investigation was submitted by resolution 172.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are availiable as SPSS .sav files and can be provided on reqeust